August 5, 2026 — Leads & Copy — Stoke Therapeutics, Inc. (Nasdaq: STOK) announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 11:00 a.m. ET.
The biotechnology company, dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, will discuss its lead investigational medicine, zorevunersen, a potential first-in-class disease-modifying treatment for Dravet syndrome.
A live webcast of the presentation, along with an archived replay, will be accessible in the Investors & News section of Stoke’s website.
Stoke Therapeutics utilizes its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach to develop antisense oligonucleotides (ASOs) designed to selectively restore naturally-occurring protein levels. Zorevunersen, the company’s first medicine in development, is currently being evaluated in a Phase 3 study and has demonstrated potential for disease modification in patients with Dravet syndrome.
The company’s initial focus is on diseases of the central nervous system and the eye that result from a loss of approximately 50% of normal protein levels, a condition known as haploinsufficiency. Stoke’s proprietary approach has shown proof of concept in other organs, tissues, and systems, indicating broad potential applications.
Zorevunersen is an investigational antisense oligonucleotide engineered to address the underlying cause of Dravet syndrome by increasing functional NaV1.1 protein production in brain cells. This mechanism of action aims to reduce seizure frequency beyond the efficacy of current anti-seizure medications and to improve neurodevelopment, cognition, and behavior.
The investigational medicine has received orphan drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Additionally, the FDA has granted zorevunersen rare pediatric disease designation and Breakthrough Therapy Designation for the treatment of Dravet syndrome with a confirmed mutation not associated with gain-of-function in the SCN1A gene. China’s Center for Drug Evaluation has also granted zorevunersen Breakthrough Therapy Designation.
Stoke has a strategic collaboration with Biogen (Nasdaq: BIIB) for the development and commercialization of zorevunersen for Dravet syndrome. Under this agreement, Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico, while Biogen holds exclusive rest of world commercialization rights. Zorevunersen is currently in clinical development, and its safety and efficacy have not yet been evaluated by any regulatory authority.
Stoke Therapeutics is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ and follow the company on LinkedIn.
Source: Stoke Therapeutics, Inc.
